To develop medical foods, drugs and therapies that address unmet medical needs by safely and effectively improving the bioavailability of naturally occuring compounds.
Sulfagenix, Inc. is a privately held biotechnology corporation located in Cleveland, Ohio built on decades of research on modifying existing molecules to improve safety, bioavailability and efficacy for new uses. SG1002, the Company’s lead molecule, is a precursor to a natural-occurring molecule for which deficits have been shown to exist in a number of serious diseases, including cardiovascular disease, type II diabetes, cancer, hypertension, Alzheimer’s Disease, asthma, & wound healing. Patient studies in Mexico demonstrated safety and generated encouraging results in several disease conditions including cancer, hypercholesterolemia, and Down’s Syndrome. Sulfagenix’s lead product, SG1002, is being developed to treat problems associated with congestive heart failure.